EGRX [NASD]
Eagle Pharmaceuticals, Inc.
Index- P/E20.33 EPS (ttm)1.77 Insider Own12.40% Shs Outstand12.84M Perf Week-16.64%
Market Cap455.82M Forward P/E11.71 EPS next Y3.07 Insider Trans0.00% Shs Float11.69M Perf Month-19.88%
Income22.80M PEG7.53 EPS next Q0.93 Inst Own85.70% Short Float8.62% Perf Quarter-18.36%
Sales272.20M P/S1.67 EPS this Y-175.90% Inst Trans-0.62% Short Ratio7.11 Perf Half Y-26.00%
Book/sh18.54 P/B1.94 EPS next Y-56.94% ROA7.50% Target Price45.50 Perf Year-26.35%
Cash/sh2.88 P/C12.45 EPS next 5Y2.70% ROE11.20% 52W Range33.72 - 58.25 Perf YTD-29.46%
Dividend- P/FCF12.91 EPS past 5Y-16.40% ROI-0.60% 52W High-38.33% Beta0.60
Dividend %- Quick Ratio1.30 Sales past 5Y-2.00% Gross Margin73.60% 52W Low6.54% ATR2.08
Employees102 Current Ratio1.80 Sales Q/Q54.10% Oper. Margin21.20% RSI (14)34.55 Volatility9.22% 5.45%
OptionableYes Debt/Eq0.21 EPS Q/Q-370.30% Profit Margin8.40% Rel Volume1.19 Prev Close35.79
ShortableYes LT Debt/Eq0.12 EarningsAug 09 BMO Payout0.00% Avg Volume141.76K Price35.92
Recom2.30 SMA20-11.12% SMA50-16.23% SMA200-23.76% Volume169,213 Change0.36%
Apr-07-21Resumed RBC Capital Mkts Outperform $52
Nov-01-18Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-31-18Downgrade Piper Jaffray Overweight → Neutral
Mar-21-18Reiterated Mizuho Underperform $37 → $40
Nov-09-17Reiterated RBC Capital Mkts Outperform $81 → $75
Sep-06-17Reiterated Mizuho Underperform $40 → $37
Jul-27-17Reiterated RBC Capital Mkts Outperform $94 → $81
Jul-27-17Reiterated Mizuho Underperform $57 → $40
May-09-17Reiterated RBC Capital Mkts Outperform $86 → $94
Jan-09-17Downgrade Mizuho Neutral → Underperform $78 → $64
Nov-16-16Downgrade Mizuho Buy → Neutral $78
Nov-03-16Upgrade Mizuho Neutral → Buy $62 → $78
Nov-03-16Reiterated RBC Capital Mkts Outperform $80 → $93
Oct-26-16Reiterated Mizuho Buy $65 → $62
Aug-16-16Reiterated Mizuho Neutral $47 → $65
Jun-20-16Downgrade Mizuho Buy → Neutral $66 → $47
May-10-16Reiterated RBC Capital Mkts Outperform $94 → $78
Mar-18-16Reiterated Mizuho Buy $81 → $71
Feb-26-16Reiterated Mizuho Buy $112 → $81
Dec-09-15Initiated Mizuho Buy $112
Aug-15-22 06:20AM  
Aug-09-22 12:00PM  
08:51AM  
08:15AM  
06:50AM  
06:45AM  
Aug-08-22 11:33AM  
Jul-28-22 04:05PM  
Jul-27-22 10:32AM  
Jul-18-22 06:50AM  
Jun-13-22 11:12AM  
Jun-09-22 07:30AM  
Jun-02-22 11:31AM  
Jun-01-22 07:26AM  
06:50AM  
May-26-22 06:50AM  
May-25-22 09:46AM  
May-09-22 01:00PM  
08:25AM  
06:50AM  
May-07-22 09:12AM  
May-04-22 11:07AM  
Apr-28-22 04:30PM  
Apr-19-22 06:50AM  
Apr-12-22 08:45AM  
Mar-28-22 11:33AM  
04:00AM  
Mar-15-22 09:40AM  
Mar-07-22 12:30PM  
08:05AM  
06:50AM  
Mar-01-22 08:38AM  
Feb-24-22 06:50AM  
Feb-10-22 11:43AM  
09:35AM  
Feb-01-22 06:50AM  
Jan-31-22 06:50AM  
Jan-18-22 06:50AM  
Jan-12-22 11:20AM  
Jan-05-22 01:39PM  
Jan-03-22 04:30PM  
Dec-29-21 11:24AM  
Dec-26-21 07:17AM  
Dec-23-21 09:24AM  
Dec-22-21 12:00PM  
Dec-20-21 11:39AM  
Dec-15-21 02:54PM  
01:54PM  
Nov-22-21 06:50AM  
Nov-11-21 06:18AM  
Nov-09-21 03:00PM  
08:13AM  
08:05AM  
06:50AM  
Oct-28-21 05:05PM  
Oct-25-21 03:01PM  
Sep-22-21 08:43AM  
Sep-07-21 06:50AM  
Sep-01-21 05:00PM  
09:41AM  
Aug-31-21 12:33PM  
12:05PM  
11:45AM  
06:50AM  
Aug-25-21 06:50AM  
Aug-09-21 04:30PM  
08:05AM  
06:50AM  
06:45AM  
Aug-02-21 03:01PM  
Jul-29-21 03:32PM  
Jul-28-21 04:30PM  
Jul-14-21 02:28AM  
Jun-24-21 06:50AM  
Jun-18-21 10:47AM  
Jun-17-21 06:50AM  
Jun-11-21 12:08PM  
May-30-21 04:06AM  
May-26-21 05:00PM  
May-14-21 05:54PM  
May-11-21 05:00PM  
May-10-21 11:30AM  
08:05AM  
06:50AM  
06:45AM  
06:45AM  
May-03-21 03:01PM  
06:50AM  
Apr-30-21 06:50AM  
Apr-29-21 04:30PM  
07:05AM  
Apr-22-21 12:28PM  
Apr-15-21 03:22AM  
Mar-15-21 04:08PM  
Mar-03-21 12:23AM  
Mar-02-21 02:00PM  
08:15AM  
06:50AM  
06:30AM  
Mar-01-21 10:15AM  
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.